CR20160061A - Formulación estable líquida de etelcalcetide (amg 461) - Google Patents
Formulación estable líquida de etelcalcetide (amg 461)Info
- Publication number
- CR20160061A CR20160061A CR20160061A CR20160061A CR20160061A CR 20160061 A CR20160061 A CR 20160061A CR 20160061 A CR20160061 A CR 20160061A CR 20160061 A CR20160061 A CR 20160061A CR 20160061 A CR20160061 A CR 20160061A
- Authority
- CR
- Costa Rica
- Prior art keywords
- etelcalcetide
- amg
- stable formulation
- formulation liquid
- liquid
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- ANIAZGVDEUQPRI-ZJQCGQFWSA-N etelcalcetide Chemical compound NC(N)=NCCC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O ANIAZGVDEUQPRI-ZJQCGQFWSA-N 0.000 title 1
- 229950006502 etelcalcetide Drugs 0.000 title 1
- 108091022127 etelcalcetide hydrochloride Proteins 0.000 title 1
- 239000007788 liquid Substances 0.000 title 1
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 abstract 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 abstract 1
- 229940122985 Peptide agonist Drugs 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
- F04D—NON-POSITIVE-DISPLACEMENT PUMPS
- F04D25/00—Pumping installations or systems
- F04D25/02—Units comprising pumps and their driving means
- F04D25/06—Units comprising pumps and their driving means the pump being electrically driven
- F04D25/0606—Units comprising pumps and their driving means the pump being electrically driven the electric motor being specially adapted for integration in the pump
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
- F01D—NON-POSITIVE DISPLACEMENT MACHINES OR ENGINES, e.g. STEAM TURBINES
- F01D15/00—Adaptations of machines or engines for special use; Combinations of engines with devices driven thereby
- F01D15/10—Adaptations for driving, or combinations with, electric generators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Mechanical Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporcionan una formulación líquida que comprende un agonista péptido del receptor que detecta calcio y un método para preparar y usar la formulación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361840618P | 2013-06-28 | 2013-06-28 | |
| PCT/US2014/044622 WO2014210489A1 (en) | 2013-06-28 | 2014-06-27 | Stable liquid formulation of amg 416 (velcalcetide) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20160061A true CR20160061A (es) | 2016-09-28 |
Family
ID=51213030
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20160002A CR20160002A (es) | 2013-06-28 | 2014-06-27 | Formulación estable líquida de etelcalcetide (amg 461) |
| CR20160061A CR20160061A (es) | 2013-06-28 | 2014-06-27 | Formulación estable líquida de etelcalcetide (amg 461) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20160002A CR20160002A (es) | 2013-06-28 | 2014-06-27 | Formulación estable líquida de etelcalcetide (amg 461) |
Country Status (38)
| Country | Link |
|---|---|
| US (4) | US9820938B2 (es) |
| EP (3) | EP3246017B1 (es) |
| JP (1) | JP6027708B2 (es) |
| KR (1) | KR102231957B1 (es) |
| CN (2) | CN105764487A (es) |
| AP (1) | AP2015008936A0 (es) |
| AR (1) | AR096773A1 (es) |
| AU (1) | AU2014302122B2 (es) |
| CA (1) | CA2916222C (es) |
| CL (1) | CL2015003738A1 (es) |
| CR (2) | CR20160002A (es) |
| CY (1) | CY1120811T1 (es) |
| DK (1) | DK3013318T3 (es) |
| EA (1) | EA030220B1 (es) |
| ES (1) | ES2633989T3 (es) |
| HR (1) | HRP20171092T1 (es) |
| HU (1) | HUE034209T2 (es) |
| IL (1) | IL243210B (es) |
| JO (1) | JO3817B1 (es) |
| LT (1) | LT3013318T (es) |
| MA (1) | MA38724B1 (es) |
| ME (1) | ME02818B (es) |
| MX (1) | MX2015017952A (es) |
| MY (1) | MY180276A (es) |
| PE (2) | PE20160549A1 (es) |
| PH (1) | PH12015502816B1 (es) |
| PL (1) | PL3013318T3 (es) |
| PT (1) | PT3013318T (es) |
| RS (1) | RS56238B1 (es) |
| SG (1) | SG11201510647TA (es) |
| SI (1) | SI3013318T1 (es) |
| SM (1) | SMT201700401T1 (es) |
| TN (1) | TN2015000569A1 (es) |
| TW (1) | TWI635874B (es) |
| UA (1) | UA115373C2 (es) |
| UY (1) | UY35636A (es) |
| WO (1) | WO2014210489A1 (es) |
| ZA (1) | ZA201600238B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2916222C (en) | 2013-06-28 | 2021-05-18 | Amgen Inc. | Stable liquid formulation of amg 416 (etelcalcetide) |
| PL3126373T3 (pl) | 2014-04-03 | 2020-07-27 | Amgen Inc. | Sposób wytwarzania amg 416 |
| US10858389B2 (en) | 2015-03-26 | 2020-12-08 | Amgen Inc. | Solution phase method for preparing etelcalcetide |
| CN106137979A (zh) * | 2015-03-31 | 2016-11-23 | 深圳翰宇药业股份有限公司 | 一种冻干粉针剂及其制备方法 |
| CN106928320B (zh) * | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| CN106928321B (zh) * | 2015-12-31 | 2019-07-26 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| CN110054662B (zh) * | 2018-01-18 | 2021-03-02 | 成都圣诺生物制药有限公司 | 一种固相合成Etelcalcetide的方法 |
| EP4149507A1 (en) | 2020-05-15 | 2023-03-22 | Amgen Inc. | Methods of treating left ventricle hypertrophy |
| CN111925415A (zh) * | 2020-08-10 | 2020-11-13 | 海南中和药业股份有限公司 | 一种维拉卡肽杂质的制备方法 |
| WO2022034545A1 (en) * | 2020-08-14 | 2022-02-17 | Aurobindo Pharma Limited | Etelcalcetide formulations for parenteral use |
| US20240207354A1 (en) | 2021-05-06 | 2024-06-27 | Amgen Inc. | Etelcalcetide formulations |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2270154A1 (en) | 1996-10-25 | 1998-04-30 | The Government Of The United States Of America As Represented By The Sec Retary, Department Of Health And Human Services | Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian cd97 alpha subunit |
| AT409081B (de) | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
| BRPI0410972C1 (pt) * | 2003-06-03 | 2021-05-25 | Novo Nordisk As | método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia |
| PL1633390T3 (pl) | 2003-06-03 | 2012-06-29 | Novo Nordisk As | Stabilizowane kompozycje farmaceutyczne peptydu glp-1 |
| US7265092B2 (en) | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
| CN101668421B (zh) | 2006-11-16 | 2014-05-21 | 凯制药公司 | 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽 |
| WO2008089491A2 (en) | 2007-01-19 | 2008-07-24 | Kai Pharmaceuticals, Inc. | Modifications of peptide compositions to increase stability and delivery efficiency |
| EP2264138B2 (en) | 2009-06-19 | 2023-03-08 | The Procter & Gamble Company | Liquid hand dishwashing detergent composition |
| ES2729051T3 (es) | 2009-07-29 | 2019-10-30 | Kai Pharmaceuticals Inc | Agentes terapéuticos para reducir los niveles de hormona paratiroidea |
| EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| WO2012075375A1 (en) * | 2010-12-02 | 2012-06-07 | Lanco Biosciences, Inc. | Delivery of parathyroid hormones by microinjection systems |
| WO2012170955A1 (en) | 2011-06-08 | 2012-12-13 | Kai Pharmaceuticals, Inc. | Therapeutic agents for regulating serum phosphorus |
| AU2012335009B2 (en) | 2011-11-10 | 2017-08-31 | Kai Pharmaceuticals, Inc. | Calcimimetics and methods for their use |
| CA2916222C (en) | 2013-06-28 | 2021-05-18 | Amgen Inc. | Stable liquid formulation of amg 416 (etelcalcetide) |
| PL3126373T3 (pl) * | 2014-04-03 | 2020-07-27 | Amgen Inc. | Sposób wytwarzania amg 416 |
-
2014
- 2014-06-27 CA CA2916222A patent/CA2916222C/en active Active
- 2014-06-27 CR CR20160002A patent/CR20160002A/es unknown
- 2014-06-27 MX MX2015017952A patent/MX2015017952A/es active IP Right Grant
- 2014-06-27 KR KR1020167002370A patent/KR102231957B1/ko active Active
- 2014-06-27 RS RS20170704A patent/RS56238B1/sr unknown
- 2014-06-27 EA EA201690099A patent/EA030220B1/ru not_active IP Right Cessation
- 2014-06-27 TW TW103122433A patent/TWI635874B/zh active
- 2014-06-27 HU HUE14742093A patent/HUE034209T2/en unknown
- 2014-06-27 PL PL14742093T patent/PL3013318T3/pl unknown
- 2014-06-27 US US14/908,481 patent/US9820938B2/en active Active
- 2014-06-27 SG SG11201510647TA patent/SG11201510647TA/en unknown
- 2014-06-27 ME MEP-2017-150A patent/ME02818B/me unknown
- 2014-06-27 MA MA38724A patent/MA38724B1/fr unknown
- 2014-06-27 WO PCT/US2014/044622 patent/WO2014210489A1/en not_active Ceased
- 2014-06-27 CN CN201480047399.7A patent/CN105764487A/zh active Pending
- 2014-06-27 UA UAA201600641A patent/UA115373C2/uk unknown
- 2014-06-27 EP EP17160312.9A patent/EP3246017B1/en active Active
- 2014-06-27 TN TN2015000569A patent/TN2015000569A1/en unknown
- 2014-06-27 CR CR20160061A patent/CR20160061A/es unknown
- 2014-06-27 CN CN202111597304.7A patent/CN114376970A/zh active Pending
- 2014-06-27 EP EP14742093.9A patent/EP3013318B1/en active Active
- 2014-06-27 JP JP2016524250A patent/JP6027708B2/ja active Active
- 2014-06-27 PE PE2015002666A patent/PE20160549A1/es unknown
- 2014-06-27 DK DK14742093.9T patent/DK3013318T3/en active
- 2014-06-27 ES ES14742093.9T patent/ES2633989T3/es active Active
- 2014-06-27 EP EP21156687.2A patent/EP3878433A1/en active Pending
- 2014-06-27 AU AU2014302122A patent/AU2014302122B2/en active Active
- 2014-06-27 PE PE2020001772A patent/PE20210413A1/es unknown
- 2014-06-27 LT LTEP14742093.9T patent/LT3013318T/lt unknown
- 2014-06-27 HR HRP20171092TT patent/HRP20171092T1/hr unknown
- 2014-06-27 PT PT147420939T patent/PT3013318T/pt unknown
- 2014-06-27 SI SI201430290T patent/SI3013318T1/sl unknown
- 2014-06-27 MY MYPI2015003044A patent/MY180276A/en unknown
- 2014-06-27 AP AP2015008936A patent/AP2015008936A0/xx unknown
- 2014-06-27 SM SM20170401T patent/SMT201700401T1/it unknown
- 2014-06-29 JO JOP/2014/0204A patent/JO3817B1/ar active
- 2014-06-30 UY UY0001035636A patent/UY35636A/es not_active Application Discontinuation
- 2014-06-30 AR ARP140102450A patent/AR096773A1/es not_active Application Discontinuation
-
2015
- 2015-12-17 IL IL243210A patent/IL243210B/en active IP Right Grant
- 2015-12-17 PH PH12015502816A patent/PH12015502816B1/en unknown
- 2015-12-28 CL CL2015003738A patent/CL2015003738A1/es unknown
-
2016
- 2016-01-12 ZA ZA2016/00238A patent/ZA201600238B/en unknown
-
2017
- 2017-07-19 CY CY171100771T patent/CY1120811T1/el unknown
- 2017-11-02 US US15/802,390 patent/US10344765B2/en active Active
-
2019
- 2019-06-03 US US16/430,322 patent/US11162500B2/en active Active
-
2021
- 2021-08-11 US US17/400,044 patent/US11959486B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20160061A (es) | Formulación estable líquida de etelcalcetide (amg 461) | |
| CL2017000654A1 (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
| CR20160141A (es) | Formulaciones de anticuerpos anti-pdl1 | |
| CL2016001586A1 (es) | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 | |
| CR20150049A (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
| CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
| AR101742A1 (es) | Agonista del receptor de calcitonina y amilina | |
| BR112015023417A2 (pt) | compostos heterocíclicos e seus usos | |
| CR20170076A (es) | Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| CL2018003045A1 (es) | Semaglutida en afecciones cardiovasculares. | |
| BR112017004745A2 (pt) | adição a um aplicador médico | |
| UY35750A (es) | Moduladores octahidro-ciclopenta[c] pirrol negativos de nr2b | |
| IL268044B1 (en) | Syringe adapter | |
| UY35751A (es) | Moduladores negativos de n-arilmetilo sulfonamida de nr2a | |
| EP3551657A4 (en) | CHIMERIC CHLOROTOXIN RECEPTORS | |
| CO7160067A2 (es) | Formulaciones de agonistas del receptor de somatostatina | |
| UY35823A (es) | Profármacos de antagonista de nmda | |
| UA116372C2 (uk) | Частинки резинату фенілефрину | |
| MX382918B (es) | Proceso para fabricar partículas de resinato de fenilefrina; partículas de resinato de fenilefrina y uso de las partículas de resinato de fenilefrina en formulaciones farmacéuticas. | |
| CR20140051A (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
| MX2015012542A (es) | Partículas de resinato de fenilefrina y su uso en formulaciones para productos farmacéuticos. | |
| UA107534U (uk) | Застосування вінборону для потенціювання аналгетичного ефекту ібупрофену | |
| CL2017003045A1 (es) | Una formulación de encapsulación para lactobacilos que permite prolongar su viabilidad | |
| UA88242U (ru) | Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства гипогликемического действия | |
| UY4217Q (es) | Configuracion aplicada en implante para uso en animales |